IRF8

Across TCGA pan-cancer cohorts, IRF8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IRF8 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IRF8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRF8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where IRF8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.944	0.886	.004	6	view →
CCRCC	DFS	Median	All	1.000	0.634	.021	4	view →
HNSC	OS	Tertile	IV	0.673	0.881	.027	4	view →
PDAC	OS	Median	III,IV	1.000	0.638	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IRF8–LUAD (DFS)

Open the LUAD breakdown →